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1 Introduction 
The Swiss Federal Office of Public Health (SFOPH) commissioned a Health Technology As-
sessment (HTA) regarding iron therapy in symptomatic patients with iron deficiency with-
out anemia (iron deficiency no anemia, IDNA) to the Basel Institute for Clinical Epidemiology 
and Biostatistics (CEB) and the Winterthur Institute of Health Economics (WIG). The scope, 
which describes the background of the HTA and elucidates the general approach, has been 
published on the SFOPH homepage.1  
This HTA followed a step-wise approach. The aim of the first step was to assess the clini-
cal effectiveness of iron therapy in symptomatic patients with IDNA, and to identify symp-
tomatic populations that benefit from the therapy. In this first step, the clinical effectiveness of 
iron therapy was assessed in comparison to any other non-iron treatment or placebo, irre-
spective of the route of iron administration. This step was conducted by CEB, and the results 
are summarized in chapter 2 of this document.  
In the second step, which will be conducted by WIG, the economic evaluation shall com-
pare parenteral versus oral iron therapy for those populations, for which a significant 
treatment effect of iron therapy (parenteral or oral) versus control could be identified during 
the first step. Based on the effectiveness results, the scope of the economic evaluation is 
outlined in chapter 4. Section 4.1 defines the objective of the economic evaluation. Section 
4.2 defines the population, the intervention, the comparator, and the outcome (PICO) which 
will be evaluated. A screening of health economic literature and publicly available HTAs for 
economic studies comparing parenteral with oral iron therapy is presented in section 4.3, and 
section 4.4 concludes with the outline of the research methodology of the economic evalua-
tion. 
1https://www.bag.admin.ch/bag/de/home/themen/versicherungen/krankenversicherung/krankenversich
erung-bezeichnung-der-leistungen/re-evaluation-hta/scoping-berichte.html 
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2 Summary of effectiveness results 
The aim of the clinical effectiveness assessment (first step of the HTA) was to identify high-
quality evidence of effectiveness of iron therapy in symptomatic populations with IDNA. 
Therefore, CEB conducted a systematic review based on RCTs comparing iron therapy (irre-
spective of the route of administration) with non-iron comparators, placebo or no therapy for 
multiple indications and endpoints. As a result, two symptomatic populations with IDNA 
were identified where iron therapy versus control showed a statistically significant 
effect: women (≥ 18 years) with fatigue and adults with restless legs syndrome (RLS).  
According to the evidence found for the first population (4 RCTs), iron therapy decreased 
fatigue severity in women with IDNA and fatigue (statistically significant effect). Two RCTs 
compared parenteral iron treatment with placebo [1, 2], and two RCTs compared oral iron 
treatment with placebo [3, 4]. The outcome of fatigue was measured by the following as-
sessments: A 22-item Piper Scale ranging from 1 (no fatigue) to 10 (very severe fatigue) over 
a follow-up of eight weeks [1], a brief inventory ranging from 0 (no fatigue) to 10 (maximum 
imaginable fatigue) with a follow-up of twelve weeks [2], a global fatigue index (MAF, range 
0-50) with a follow-up of twelve weeks [3], and a VAS (range 1-10) with a follow-up of four 
weeks [4]. No RCTs were identified which compared iron therapy to any other active com-
parator in women with IDNA and fatigue. 
For the RLS population, the evidence showed that iron therapy reduced RLS symptom se-
verity (statistically significant effect). Seven RCTs were included in this analysis of adults with 
IDNA and RLS. Five RCTs compared parenteral iron treatment with placebo [5-9], one RCT 
compared oral iron therapy with placebo [10] and one RCT compared oral iron therapy with 
pramipexole [11]. All seven RCTs assessed RLS symptom severity on a scale ranging from 
0-402 and with follow-up periods ranging from two to twelve weeks. 
For both populations, potentially different effects of parenteral and oral iron were assessed 
between subgroups of trials including patients receiving either oral or parenteral iron (test of 
interaction). However, the number of available RCTs was too limited and no conclusion of 
differential effects between the two routes of administrations could be drawn, based on for-
mal inspection of difference in effect sizes across these subgroups of trials. The test of inter-
action for a different effect size in trials of oral versus parental iron therapy was not statisti-
cally significant.   
2 Assessments by either the International Restless Legs Syndrome (IRLS) study group severity scale, 
IRLS severity scale, IRLS group rating scale, ORLS symptoms severity score, or IRLS survey. 
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As predefined in the scope of the clinical effectiveness assessment (SFOPH3), only RCTs 
with a non-iron comparator were included. Among the included trials, no RCTs with a head-
to-head comparison of oral iron vs. parenteral iron were identified. 
3  
https://www.bag.admin.ch/dam/bag/de/dokumente/kuv-leistungen/bezeichnung-der-leistungen/Re-
Evaluation-HTA/iron-therapy--iron-deficiency-without-anemia-final-scope-2017 .pdf 
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3 Systematic search for direct comparison oral versus parenteral  
It is the primary goal of the economic evaluation to compare cost-effectiveness of oral versus 
parenteral iron therapy in those populations for which effectiveness has been shown in the 
first step of the HTA. For such an analysis, results from direct comparisons are desirable. 
Head-to-head comparison by RCTs represent the most reliable information for such econom-
ic evaluation.   
In contrast to the first step of the HTA, in this part of the analysis also RCTs are eligible 
which did not include a non-iron comparator, as the focus is now on the two populations for 
which effectiveness of iron therapy has been demonstrated in the first step of the HTA. 
Therefore, an additional literature search for iron-only head-to-head comparisons of oral ver-
sus parenteral iron therapy in IDNA patients with fatigue or restless legs syndrome was con-
ducted. The systematic search was performed in Medline and the Cochrane Central Register 
of Controlled Trials (CENTRAL) on 30 October 2017. The search strategy was identical to 
the one used for the clinical effectiveness assessment, except that terms describing the two 
populations were added. Details about the search strategy are outlined in the Appendix.  
After removal of duplicates, 213 records remained for screening of title/abstract. In a next 
step, the full-text of 17 records were assessed. None of the 213 records satisfied the in-
clusion and exclusion criteria (see Table 1 and Figure 1).  
Table 1: PICO and inclusion and exclusion criteria 
Population Inclusion: 
• 1. Target population: Adult (≥18 years) females with IDNA and fatigue 
• 2. Target population: Adults (≥18 years) with IDNA and restless legs syndrome  
• No other cause should have been identified for the symptoms that treatment with 
iron aims to alleviate 
Exclusion: 
• Studies with athletes 
• Studies including patients who are known to suffer from one of the following under-
lying diseases: 
o Chronic heart failure 
o Renal failure, chronic kidney disease, dialysis 
o Chronic liver failure 
o Chronic inflammatory disease in particular inflammatory bowel disease 
o Achlorhydria, atrophic gastritis, gastric resection 
o Acute and chronic infections 
o Malignancy 
Intervention /  
Comparator 
Parenteral versus oral iron therapy 
Outcome Health and safety outcomes 
Study design Only randomized controlled trials and quasi-randomized trials in high-income countries 
were included 
Report type Poster presentations and conference abstracts were excluded 
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 Figure 1: Prisma flow chart 
 
 
Although none of the studies satisfied the predefined criteria, two RCTs are in our opinion 
noteworthy. In one RCT conducted by Birgegard et al. (2010), regular blood donors with ID-
NA and at least five previous whole blood donations were investigated [12]. A subgroup of 22 
donors out of 120 was diagnosed with restless legs syndrome (8 in the parenteral group and 
14 in the oral group). Hence, the population in general is not considered symptomatic. The 
severity was assessed using the International Restless Legs Syndrome Study Group Severi-
ty Scale. However, the findings of this study remained inconclusive, and the number of pa-
tients was low. In addition, a protocol of an ongoing RCT was found, which directly compares 
oral with parenteral iron therapy in blood donors with iron deficiency [13]. This RCT, howev-
er, has not been published yet. 
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4 Economic evaluation 
The clinical effectiveness assessment by CEB identified two symptomatic IDNA popula-
tions which benefit from iron therapy: Women with fatigue and adults with RLS. This was 
concluded based on the clinical evidence provided by RCTs, which compare iron treatment 
with placebo. The economic evaluation is restricted to these two populations. 
During the effectiveness assessment and the additional literature search described in the 
previous chapter, no data from RCTs with a direct comparison of parenteral and oral iron 
therapy could be identified. Furthermore, it was considered that no reliable estimation of dif-
ferential effects can be expected from an indirect comparison of the available RCT data from 
the first step of this HTA. 
Consequently, based on current available indirect evidence from RCTs, there is insufficient  
evidence for a clinically relevant difference in treatment effects of parenteral versus oral iron 
therapy. It has therefore been decided in accordance with the SFOPH to restrict the econom-
ic evaluation to a cost-comparison analysis, rather than a cost-effectiveness analysis. 
4.1 Objective of the economic evaluation 
A cost-comparison analysis of parenteral versus oral iron therapy for IDNA patients with 
fatigue or RLS will be conducted. The main objective of the economic evaluation is to quan-
tify the costs of parenteral and oral iron therapy from a health care payer perspective 
(OKP4, social insurance, including both outpatient and inpatient costs) and to compare them, 
as well as to perform a budget impact analysis. The following two key research questions will 
be addressed: 
• What are the direct medical costs of oral iron therapy versus parenteral iron therapy 
in IDNA patients with fatigue or RLS? 
• What is the budget impact of different iron treatment strategies in IDNA patients with 
fatigue or RLS? 
As the study will be conducted from a health care payer perspective (OKP, social insurance), 
indirect costs and additional costs for patients (such as e.g.  travel costs) will not be consid-
ered.  
4 Obligatorische Krankenpflegeversicherung 
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4.2 PICO 
The results of the clinical effectiveness assessment showed statistically significant effects on 
fatigue severity or RLS symptom severity when iron therapy was compared to placebo in 
IDNA women with fatigue or IDNA adults with RLS, respectively. Therefore, the economic 
evaluation will investigate these two symptomatic populations with IDNA and consequently 
two PICOs are proposed. It will thereby be analyzed whether the cost comparison between 
parenteral and oral iron therapy yields any different results across the two populations of in-
terest. 
 
PICO 1: Women with fatigue 
Population:  IDNA women (at least 18 years of age) with fatigue and eligible for oral thera-
py (i.e. no chronic inflammatory bowel disease) 
Intervention:  Parenteral therapy with iron  
Comparator: Oral therapy with iron with possible switch to parenteral therapy 
Outcome:  Direct medical costs (drug costs, physician visits, drug administration costs, 
costs due to management of adverse events both outpatient and inpatient) 
 
PICO 2: Restless legs syndrome 
Population:  Adults (at least 18 years of age) with IDNA and with RLS and eligible for oral 
therapy (i.e. no chronic inflammatory bowel disease) 
Intervention:  Parenteral therapy with iron  
Comparator:  Oral therapy with iron with possible switch to parenteral therapy 
Outcome:  Direct medical costs (drug costs, physician visits, drug administration costs, 
costs due to management of adverse events both outpatient and inpatient) 
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4.3 Results of systematic search of economic literature 
The aim of this step was to gain an overview of applied modelling techniques and of previous 
outcomes of health economic evaluations in the relevant therapeutic area. First, a search for 
health economic studies and HTAs of therapies was performed on 19 September 2017 with-
out time restrictions, specifically for patients with IDNA. The search terms and number of hits 
are listed in Table 2. No search filters were applied. 
Table 2: Literature search for economic studies in patients with IDNA 
Step Search terms PubMed Cochrane Library 
Web of 
Science 
1 „latent iron deficiency“ 128 15 51 
2 „iron-deficient erythropoiesis“ 155 24 145 
3 ("latent iron deficiency" OR "iron-deficient erythropoiesis") 280 32 195 
4 (("latent iron deficiency" OR "iron-deficient erythropoiesis") 
AND cost) 
12 0 8 
5 (("latent iron deficiency" OR "iron-deficient erythropoiesis") AND ("cost effectiveness" OR "cost-effectiveness")) 0 0 0 
6 (("latent iron deficiency" OR "iron-deficient erythropoiesis") AND "budget impact") 0 0 0 
 
The number of hits decreased drastically from step three to step four, as economic search 
terms (costs, cost-effectiveness, budget impact) were added to the medical terms of IDNA. 
The titles of the 20 hits from step 4 were screened. This lead to the identification of one study 
that analyzed health insurance claims data to estimate the total costs of outpatient iron ther-
apy, which was conducted from a statutory health insurance perspective in Switzerland for 
the years 2006 to 2010 [14]. However, this study did not focus on IDNA and did not compare 
treatment costs on a patient level. Hence, this first step of the literature search did not yield 
any studies relevant to our HTA. Therefore, the search was widened to a broader definition 
of iron deficiency in general, also allowing for anemia (Table 3). 
Table 3: Literature search for economic studies in patients with iron deficiency 
Step Search terms PubMed Cochrane Library 
Web of 
Science 
1 (("iron deficiency" OR "iron-deficiency anemia") AND cost) 547 90 497 
2 (("iron deficiency" OR "iron-deficiency anemia") AND ("cost-effectiveness" OR "cost effectiveness")) 
68 1 80 
3 (("iron deficiency" OR "iron-deficiency anemia") AND "budget impact") 
7 0 5 
 
The titles of the 161 hits from steps 2 and 3 were screened. Of 28 studies the abstract was 
read, leading to six relevant cost-effectiveness studies and three relevant budget impact 
analyses (Table 4). 
Four studies assessed cost-effectiveness of parenteral iron therapy versus placebo in chron-
ic heart failure patients with iron deficiency [15-18]. The time horizon was 24 weeks and the 
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QALY-gain relatively small (0.037 QALYs in the case of Gutzwiller et al., 2012 [15]). The cost 
assessment included drug costs, drug administration costs, and chronic heart failure related 
hospitalization costs. The ICER amounted to 4,414 GBP per QALY [15], 8,194 EUR per 
QALY [16], 22,192 USD per QALY [17], and 6,123 EUR per QALY [18], respectively (Table 
4). Another study conducted a cost comparison analysis comparing three intravenous iron 
treatments in patients with iron deficiency anemia over one year [19]. This study considered 
drug costs, drug administration costs, costs due to management of adverse events, patient 
productivity loss, and patient travelling costs. A further study modelled the cost-effectiveness 
of parenteral versus oral iron therapy in patients with chronic kidney disease and iron defi-
ciency anemia [20]. This study modelled the cost-effectiveness over the entire lifespan. The 
QALY-gain was dependent on the age group and ranged from 0.225 QALYs (60-75 year age 
group) to 0.574 QALYs (18-25 year age group). Costs per QALY gained amounted to 34,660 
USD (Table 4). 
Three relevant budget impact analyses were identified. One budget impact analysis com-
pared ferric carboxymaltose with iron sucrose in patients receiving parenteral iron therapy in 
Switzerland, irrespective of the indications [21]. This study was based on prices from the 
“Spezialitäten Liste”, “Mittel- und Gegenstände-Liste” and TARMED positions. Another study 
compared the budget impact of different parenteral iron therapies in patients with iron defi-
ciency anemia in the UK [22]. The third study analyzed parenteral iron therapy versus no iron 
therapy in chronic heart failure patients with iron deficiency anemia in Germany [23]. 
There exists a HTA comparing oral versus parenteral iron therapy in patients with iron defi-
ciency anemia and in patients with symptomatic, severe iron deficiency without anemia con-
ducted by the Swiss Medical Board [24]. However, results were not reported separately for 
each population, as the analysis does not concern the same research question as the pre-
sent HTA commissioned by the SFOPH. In this HTA several assumptions were made to 
compare QALYs using the Karnofsky-Index. Over a time horizon of 1-year, the QALY-gain 
for parenteral compared to oral iron therapy was 0.025 QALYs. This QALY-gain was based 
on the assumption that symptoms disappear within 3 weeks with parenteral iron therapy 
compared to 16 weeks with oral iron therapy5. Costs were analyzed from a health care payer 
perspective and included drug costs (oral and parenteral therapy) and drug administration 
costs (parenteral therapy). Costs were estimated at CHF 100 per patient and 16-week treat-
ment for the oral therapy (drug costs only), and at CHF 510 per patient and single admin-
5 In the present HTA commissioned by the SFOPH, the RCTs identified in the effectiveness analysis 
and the additional search for RCTs directly comparing oral versus intravenous iron therapy do not 
allow for any distinction of the onset of effect between oral and intravenous iron therapy because time 
until onset of effect was not reported in any of the identified RCTs. 
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istration (1’000 mg) for the parenteral therapy (drug costs plus expendable materials, admin-
istration, and monitoring). This leads to an ICER of CHF 16’400/QALY.  
No study reporting results specifically for the comparison of oral versus parenteral iron thera-
py in patients with IDNA was found. Furthermore, no model was found that could be adopted 
to answer the present research question. Consequently, an own model needs to be built 
specifically for the economic evaluation of this HTA. 
Table 4:  Identified cost-effectiveness studies and budget impact analyses for paren-
teral or oral iron therapy of iron deficiency 
Ref. Author Year Study design 
Interven-
tion/Com-
parator 
Country Main Results Remarks 
Cost-effectiveness studies         
[15] Gutzwiller 
FS, 
Schwenkgle
nks M, Blank 
PR, Braun-
hofer PG, 
Mori C, 
Szucs TD, 
Ponikowski 
P, Anker SD 
2012 C/E 
analysis 
based 
on RCT 
Parenteral 
iron therapy 
vs. paren-
teral place-
bo 
United 
Kingdom 
ICER = 4,414 
GBP per QALY 
gained (QoL 
measured by self-
reported Eu-
roQuol), consider-
ing direct medical 
costs in primary 
care 
Chronic heart failure, 
iron deficiency both 
with and without ane-
mia, follow-up 24 
weeks, very small 
difference in QALY 
(intervention vs. con-
trol) of 0.037 (boot-
strap-based 95% CI 
0.017-0.060) 
[16] Hofmarcher 
T, Borg S 
2015 C/E 
analysis 
based 
on RCT 
Parenteral 
iron therapy 
vs. paren-
teral place-
bo 
Sweden ICER = 75,389 
SEK (8,194 EUR) 
per QALY gained 
(QoL measured 
by self-reported 
EuroQuol), con-
sidering direct 
medical costs in 
primary care 
Use of the same clini-
cal data as Gutzwiller 
et al. (2012) with the 
perspective of the 
Swedish healthcare 
system; Chronic heart 
failure, iron deficiency 
both with and without 
anemia, follow-up 24 
weeks, very small 
difference in QALY 
(intervention vs. con-
trol) of 0.037 (boot-
strap-based 95% CI 
0.017-0.060) 
[17] Lim EA, 
Sohn HS, 
Lee H, Choi 
SE 
2014 C/E 
analysis 
based 
on RCT 
Parenteral 
iron therapy 
vs. paren-
teral place-
bo 
South 
Korea 
ICER = 22,192 
USD per QALY 
gained (QoL 
measured by New 
York Heart Asso-
ciation (NYHA) 
functional class), 
considering direct 
medical costs in 
primary care 
Use of the same clini-
cal data as Gutzwiller 
et al. (2012) with the 
perspective of the 
South Korean 
healthcare system; 
Chronic heart failure, 
iron deficiency both 
with and without ane-
mia, follow-up 24 
weeks, very small 
difference in QALY 
(intervention vs. con-
trol) of 0.021 (accord-
ing to NYHA) 
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[18] Comín-Colet 
J, Rubio-
Rodríguez 
D, Rubio-
Terrés C, 
Enjuanes-
Grau C, 
Gutzwiller 
FS, Anker 
SD, Poni-
kowski P 
2015 C/E 
analysis 
based 
on RCT 
Parenteral 
iron therapy 
vs. paren-
teral place-
bo 
Spain ICER = 6,123 
EUR per QALY 
gained (QoL 
measured by self-
reported Eu-
roQuol), consider-
ing direct medical 
costs in primary 
care 
Use of the same clini-
cal data as to Gutzwill-
er et al. (2012) with the 
perspective of the 
Spanish healthcare 
system; Chronic heart 
failure, iron deficiency 
both with and without 
anemia, follow-up 24 
weeks, very small 
difference in QALY 
(intervention vs. con-
trol) of 0.037 (boot-
strap-based 95% CI 
0.017-0.060) 
[19] Fragoulakis 
V, Kourlaba 
G, Goume-
nos D, Kon-
stantoulakis 
M, Maniada-
kis N 
2012 C/M 
analysis 
and 
budget 
impact 
analysis  
Three dif-
ferent par-
enteral iron 
therapies 
directly 
compared 
(no place-
bo) 
Greece Dominance 
(costs) of Ferinject 
over Venofer and 
CosmoFer; direct 
medical costs, 
productivity losses 
and travel costs 
for patients are 
considered 
Iron deficiency anemia 
in inpatient setting 
(surgical patients or 
patients hospitalized 
due to a disease relat-
ed to chronic or acute 
blood loss) or in an 
outpatient setting (non-
dialysis chronic kidney 
disease patients); no 
evidence of significant 
difference in clinical 
effectiveness across 
the three therapies, 
therefore C/M analysis 
is performed  
[20] Wong G, 
Howard K, 
Hodson E, 
Irving M, 
Craig JC 
2013 C/E 
analysis 
based 
on 
multiple 
RCTs 
Parenteral 
iron therapy 
vs. oral iron 
therapy 
Australia ICER = 34,660 
USD per QALY; 
With a QALY 
threshold of 
50,000 USD, in 
90% of the simu-
lated cases paren-
teral therapy is 
cost-effective vs. 
oral, direct medi-
cal costs are 
considered   
Chronic kidney disease 
patients with iron defi-
ciency anemia, eco-
nomic evaluation com-
paring parenteral with 
oral iron therapy alt-
hough no clinical trial is 
available directly com-
paring the two (clinical 
trials compare one of 
the two vs. placebo), 
difference in clinical 
effectiveness in favor 
of parenteral therapy 
on average but not 
statistically significant 
at 95% level 
Budget impact studies         
[21] Brock E, 
Braunhofer 
P, Troxler J, 
Schneider H 
2014 Budget 
impact 
analysis 
Parenteral 
iron therapy 
with iron 
sucrose vs. 
ferric car-
boxymalt-
ose 
Switzer-
land 
Parenteral iron 
therapy with ferric 
carboxymaltose 
was associated 
with cost savings 
of 30-44% per 
patient and treat-
ment cycle, budg-
et impact de-
creased by 22-31 
million CHF 
across all indica-
tions for the year 
2009 
Costs calculated for all 
iron treatments reim-
bursed by Swiss OKP 
("Obligatorische 
Krankenpflegeversi-
cherung"), hence not 
restricted to IDNA; 
based on Swiss 
TARMED, MiGeL ("Mit-
tel- und Gegenstand-
sliste") and SL ("Spe-
zialitätenliste") prices, 
savings mainly due to 
reduced lab costs 
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[22] Pollock RF, 
Muduma G 
2017 Budget 
impact 
analysis 
Four differ-
ent paren-
teral iron 
therapies 
directly 
compared 
United 
Kingdom 
Monofer and 
Cosmofer (both 
iron sucrose) are 
cost saving com-
pared to Ferinject 
(costs reduced by 
143 GBP per 
patient) and 
Venofer (costs 
reduced by 2,149 
GBP), requiring 
fewer infusions; 
The active agent 
of Ferinject is iron 
carboxymaltose 
and of Venofer it 
is iron sucrose   
Iron deficiency anemia 
[23] Theidel U, 
Väätäinen S, 
Martikainen 
J, Soini E, 
Hardt T, 
Doehner W 
2017 Budget 
impact 
analysis 
Parenteral 
iron therapy 
vs. no-iron 
Germany Cost-savings of 
40 EUR per pa-
tient per year due 
to reduced and 
shorter hospitali-
zations and im-
proved status of 
patients, direct 
medical costs are 
considered 
Anemic patients with 
chronic heart failure 
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4.4 Method of cost comparison and budget impact analysis   
The direct medical costs of the different routes of administration will be modelled with a deci-
sion tree. The time horizon of the analysis is one year. Based on the clinical experts involved 
in this project, a 3 months period is the typical duration of one treatment cycle (medication + 
re-evaluation) for both oral and parenteral iron application in patients with IDNA and fatigue 
or RLS in Switzerland. Furthermore, about 80% to 90% of the patients are successfully treat-
ed (meaning rise of laboratory parameter(s) and symptom relief) within the first treatment 
cycle. However, some patients require up to three treatment cycles (9 months) to fully recov-
er. For RLS patients it was not possible to make assumptions based on expert experience 
but it was considered, that a similar time horizon can be applied given that the RCTs in this 
indication used similar treatment durations as the RCTs investigating fatigue (oral iron treat-
ment for 24 weeks was the maximum in the RCTs investigating RLS). Consequently, for both 
populations a time horizon of one year is considered long enough to model all relevant con-
sequences related to the initial decision regarding first-line treatment strategy. Different dos-
ages and frequencies of administration across the different therapies will be taken into ac-
count. Considered health states are compliance, compatibility, and severe side effects (e.g. 
phlebitis, severe hypersensitivity reactions as derived from the known effectiveness studies). 
Empirical evidence on probabilities will stem from the above-mentioned clinical trials, as well 
as from secondary data sources, as an extensive search of clinical literature will be conduct-
ed (both RCTs and other study designs including empirical evidence of transition probabili-
ties). It is to consider that the probabilities of compliance, compatibility, and severe side ef-
fects, may possibly not be available specifically for the populations with fatigue and restless 
legs syndrome, or may not necessarily differ between these two populations. If applicable 
according to clinical knowledge, a potential lack of RCT-based, population-specific probabili-
ties will be resolved by adopting probabilities from another population or setting. For exam-
ple, probabilities stemming from RCTs of non-anemic patients with fatigue have the highest 
priority for the decision tree of the respective population. Whenever an according probability 
is missing, RCTs will be checked whether data from other populations or non RCT data 
might be a suitable approximation. The clinical experts will be consulted in such a case. 
Drug costs will be based on prices from the “Spezialitätenliste (SL)”. Drug administration 
costs as well as costs due to management of adverse events will be based on TARMED po-
sitions, the “Analysenliste (AL)”, and the “Mittel- und Gegenständeliste (MiGeL)”. If inpatient 
treatment is a causal result of the iron therapy (e.g. due to a severe adverse event), its costs 
will be included based on SwissDRG. 
Uncertainty will be addressed by a univariate sensitivity analysis. This analysis aims to identi-
fy the parameters whose uncertainty has the largest influence on the result. In addition, a 
15 
 
probabilistic sensitivity analysis, in which all parameters with uncertainty will be varied within 
their confidence intervals, shall yield a credible interval for the estimated result.  
The budget impact will likewise be estimated from a health care payer perspective and will 
be based on the resulting direct medical costs and epidemiologic data available for Switzer-
land.  
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Appendix: Search strategy for studies directly comparing oral ver-
sus intravenous iron therapy 
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE(R) Daily, Ovid MEDLINE and Versions(R) 
Search date: 30.10.2017, 8.25 am 
Search strategy: 
1     ferrous.ti,ab. (11808) 
2     ferric.ti,ab. (17369) 
3     iron.ti,ab. (167042) 
4     1 or 2 or 3 (180094) 
5     exp Iron/ad, tu, th [Administration & Dosage, Therapeutic Use, Therapy] (7964) 
6     exp Iron Compounds/ad, tu, th [Administration & Dosage, Therapeutic Use, Therapy] (9348) 
7     exp iron, dietary/ (2940) 
8     4 or 5 or 6 or 7 (185517) 
9     therapy.ti,ab. (1644005) 
10     administration.ti,ab. (786244) 
11     intake.ti,ab. (242338) 
12     supplement*.ti,ab. (290856) 
13     replac*.ti,ab. (390570) 
14     therapeutic.ti,ab. (868120) 
15     administered.ti,ab. (512949) 
16     exp therapeutics/ (4157779) 
17     treat*.ti,ab. (4976609) 
18     exp Dietary Supplements/ (63529) 
19     exp Pharmaceutical Preparations/th [Therapy] (253) 
20     9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (9404795) 
21     gluconate.ti,ab. (6859) 
22     sucrose.ti,ab. (63146) 
23     dextran.ti,ab. (33373) 
24     carboxymaltose.ti,ab. (289) 
25     isomaltoside.ti,ab. (96) 
26     ferumoxytol.ti,ab. (296) 
27     21 or 22 or 23 or 24 or 25 or 26 (102449) 
28     sulphate.ti,ab. (34897) 
29     sulfate.ti,ab. (133982) 
30     gluconate.ti,ab. (6859) 
31     lactate.ti,ab. (97717) 
32     bisglycinate.ti,ab. (33) 
33     citrate.ti,ab. (40906) 
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34     edta.ti,ab. (35087) 
35     fumarate.ti,ab. (8206) 
36     succinate.ti,ab. (22386) 
37     saccharate.ti,ab. (140) 
38     orthophospate.ti,ab. (3) 
39     pyrophosphate.ti,ab. (14907) 
40     electrolytic.ti,ab. (6267) 
41     28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 (383265) 
42     randomized controlled trial.pt. (497868) 
43     controlled clinical trial.pt. (99285) 
44     randomized.ab. (434647) 
45     randomised.ab. (87593) 
46     placebo.ab. (203156) 
47     clinical trials as topic.sh. (195751) 
48     randomly.ab. (299524) 
49     Random*.tw. (1018137) 
50     trial.ti. (196266) 
51     42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 (1457594) 
52     exp animals/ not humans.sh. (4683036) 
53     51 not 52 (1335929) 
54     8 and (20 or 27 or 41) and 53 (6129) 
55     exp fatigue/ (27482) 
56     fatigue.ti,ab. (83048) 
57     exp lethargy/ (367) 
58     tired.ti,ab. (1818) 
59     tiredness.ti,ab. (3515) 
60     55 or 56 or 57 or 58 or 59 (96239) 
61     exp restless legs syndrome/ (3341) 
62     restless legs syndrome.ti,ab. (3460) 
63     restless leg syndrome.ti,ab. (460) 
64     restless.ti,ab. (5283) 
65     leg.ti,ab. (83701) 
66     legs.ti,ab. (31051) 
67     64 and (65 or 66) (4182) 
68     Willis.ti,ab. (3232) 
69     Ekbom.ti,ab. (190) 
70     disease.ti,ab. (2775008) 
71     68 and 69 and 70 (114) 
72     61 or 62 or 63 or 67 or 71 (4703) 
73     60 or 72 (100672) 
74     8 and (20 or 27 or 41) and 73 (769) 
20 
 
75     74 not 52 (739) 
76     8 and (20 or 27 or 41) and 73 and 53 (130) 
 
Database: CENTRAL 
Search date: 30.10.2017, 9.08 am 
Search strategy: 
#1 iron:ti,ab,kw  6496 
#2 ferrous:ti,ab,kw  1030 
#3 ferric:ti,ab,kw  880 
#4 [25-#3]  6882 
#5 MeSH descriptor: [Iron] explode all trees 1901 
#6 #1 or #2 or #3 or #5  6882 
#7 therapy:ti,ab,kw  364298 
#8 administration:ti,ab,kw  199836 
#9 intake:ti,ab,kw  32439 
#10 supplement*:ti,ab,kw  42067 
#11 replac*:ti,ab,kw  25996 
#12 therapeutic:ti,ab,kw  60186 
#13 administered:ti,ab,kw  74199 
#14 treat*:ti,ab,kw  546944 
#15 MeSH descriptor: [Therapeutics] explode all trees 288047 
#16 MeSH descriptor: [Dietary Supplements] explode all trees 10246 
#17 MeSH descriptor: [Pharmaceutical Preparations] explode all trees 64721 
#18 [26-#17]  803100 
#19 (gluconate or sucrose or dextran or carboxymaltose or isomaltoside or ferumoxytol):ti,ab,kw 
 4448 
#20 (sulphate or sulfate or gluconate or lactate or bisglycinate or citrate or edta or fumarate or 
succinate or saccharate or orthophospate or pyrophosphate or electrolytic):ti,ab,kw  25386 
#21 #6 and (#18 or #19 or #20)  5906 
#22 MeSH descriptor: [Fatigue] explode all trees 2431 
#23 fatigue:ti,ab,kw  20411 
#24 MeSH descriptor: [Lethargy] explode all trees 6 
#25 tired:ti,ab,kw  207 
#26 tiredness:ti,ab,kw  740 
#27 [27-#26]  20935 
#28 MeSH descriptor: [Restless Legs Syndrome] explode all trees 232 
#29 restless legs syndrome:ti,ab,kw  535 
#30 restless:ti,ab,kw  669 
#31 leg*:ti,ab,kw  18049 
#32 syndrome:ti,ab,kw  52820 
#33 {and #30-#32}  544 
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#34 willis:ti,ab,kw  69 
#35 ekbom:ti,ab,kw  18 
#36 disease:ti,ab,kw  230810 
#37 [28-#36]  16 
#38 #28 or #29 or #33 or #37  548 
#39 #27 or #38  21417 
#40 #6 and (#18 or #19 or #20) and #39  193 
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